Author : Jiang-Jiang Qin,Wei-Dong Zhang,Huizi Jin,Sanjay K. Srivastava
Publisher : Frontiers Media SA
Page : 699 pages
File Size : 47,5 Mb
Release : 2024-01-11
Category : Medical
ISBN : 9782832541982
Multi-targeted Natural Products as Cancer Therapeutics: Challenges and Opportunities, Volume I, 2nd edition by Jiang-Jiang Qin,Wei-Dong Zhang,Huizi Jin,Sanjay K. Srivastava Pdf
This Research Topic is part of a series with: Multi-targeted Natural Products as Cancer Therapeutics: Challenges and Opportunities, Volume II Cancer remains a leading cause of disease-related deaths worldwide, despite recent advances in our understanding of cancer initiation, progression, and metastasis. Chemotherapy and radiotherapy have been used as standard non-surgical treatments of human cancer for decades, however, the survival rates of patients with cancer, especially those with advanced diseases are still very low due to the high toxicities of these treatments as well as the severe side effects. This fact has motivated researchers to discover new cancer therapeutics with minimum side effects, which intensively promotes the rapid development of single specific molecule-targeted therapies (SSMTT). Many efforts have been made in world-wide cancer drug discovery research and several single molecule-targeted therapies have been successfully developed. Unfortunately, most of the investments failed because cancer is a genetic disease and always harbors multiple alternations of molecules or genes at the genomic, genetic and epigenetic levels. The inhibition of a single molecule or signaling pathway by SSMTT frequently results in a hyperactive compensation of other cancer-related molecules and signaling pathways as well as the subsequent development of drug resistance. Therefore, identifying multi-targeted therapies, i.e. drugs that are able to target multiple cancer-related genes, proteins, or signaling pathways is a more promising way to success in developing new cancer therapeutics. Natural products, especially those from traditional Chinese medicine and folk remedies in other countries are an extraordinarily important source for new drug discovery over the past decades. Of note, many natural products have often been demonstrated to target several crucial genes or proteins in cancer-related signaling networks and exert synergistic effects. For example, Japonicone A, a dimeric sesquiterpenoid from the medicinal plant Inula japonica, has been found to inhibit tumor growth and metastasis by dually targeting the TNF-α/NF-κB and p53/MDM2 signaling pathways. Traditionally, researchers have believed that the multi-targeting mechanisms of natural products have limited their use in cancer treatment due to the low specificity and potential side effects. The growing interest in developing multi-targeted cancer therapies may provide another golden opportunity to develop natural products as new cancer therapeutics. Nevertheless, critical investigations for a comprehensive understanding of the molecular mechanisms of natural products also mean more challenges. Our long-term goals are to fully understand the molecular targets and mechanisms of action of anticancer natural products and develop them as novel cancer preventive and therapeutic agents. The specific goal of this Research Topic is to bring together the recent findings of newly identified anticancer natural products, especially those with multiple molecular targets. Papers (Original Research articles or Reviews) which discuss the in vitro and in vivo efficacy and pharmacological and toxicological properties of natural products are also welcome to be submitted. Guidelines for the conception and review of submissions As many anticancer drugs working as cytotoxic compounds have non-selective effects annihilating their potential therapeutic benefits, manuscripts are advised to provide evidence of a significant selectivity towards cancer cells (vs. healthy cells). Specifically, if the studied anticancer drug or modality does not target an oncogenic pathway, the authors should make every effort possible to prove that the cytotoxic or cytostatic effects they have identified exhibit selectivity for cancer cells (ideally 1 log difference in EC50 or IC50) vs. non-malignant cells (eg, fibroblasts or primary culture of cells). The authors should also demonstrate the applicability of their anticancer modalities on a minimum of two well-authenticated cancer cell lines (ideally originating from distinct organs/tissues). For manuscripts dealing with plant extracts or other natural substances/compounds, the composition and the stability of the study material must be described in sufficient detail. In particular, for extracts, chromatograms with characterization of the dominating compound(s) are requested. The level of purity must be proven and included. Please refer to the Four Pillars of Best Practice in Ethnopharmacology, a subset of which concerning general standards in natural product research are applied to all such studies in all sections of Frontiers in Pharmacology.